publication date: Mar. 20, 2020

Letter to the Editor

COVID-19 and Cancer Consortium

To Whom it May Concern:

We are living in unprecedented times. There remains a great deal of uncertainty about COVID-19 and its effects on individuals, especially the elderly and the immunocompromised. Cancer patients form a unique subset of individuals who are often both elderly and immunocompromised, may have significant comorbidities, and may be actively receiving treatment.

In order to better understand the scope and severity of infection in cancer patients, we are soliciting information under the auspices of a multi-institutional collaboration, the COVID-19 and Cancer Consortium (CCC19). If you have knowledge of a cancer patient who has been affected by COVID-19, we ask you to complete a short REDCap survey which can be accessed here.

There is no compensation for this study, which has been determined to be IRB exempt (Vanderbilt IRB #200467). We will also ask you to optionally provide your name and email address, in case you would like to be contacted for clarifications or to participate in other studies.

If you have any questions please contact the Vanderbilt principal investigator, Dr. Jeremy Warner MD, MS (

We thank you kindly for considering a contribution to this registry.


  • Mike Thompson, MD, PhD, FASCO (Aurora Health Care)

  • Paul Fu, Jr., MD, MPH, FAAP, FAMIA; H. Jack West, MD (City of Hope)

  • Shilpa Gupta, MD; Nathan Pennell, MD, PhD, FASCO (Cleveland Clinic)

  • Ziad Bakouny, MD, MSc; Toni K. Choueiri, MD; Jack (John) Steinharter (Dana-Farber Cancer Institute)

  • Tian Zhang, MD, MHS (Duke University)

  • Mehmet Asim Bilen, MD (Emory University/Winship Cancer Institute)

  • Peter C. Yang, MD (

  • Clarke A. Low, MD; David M. Gill, MD; Terence D. Rhodes, MD; Mark A. Lewis, MD (Intermountain Health Care)

  • Nilo Azad, MD (Johns Hopkins University)

  • Genevieve M. Boland, MD, PhD, FACS; Justin F. Gainor, MD (Massachusetts General Hospital)

  • Thorvardur R. Halfdanarson, MD (Mayo Clinic)

  • Nizar M. Tannir, MD, FACP; Vivek Subbiah, MD (MD Anderson Cancer Center)

  • Deborah B. Doroshow, MD, PhD; Matthew Galsky, MD (Mount Sinai/Tisch Cancer Institute)

  • Rafeh Naqash, MD (NCI Bethesda)

  • Wasif Saif, MD, MBBS (Northwell Health)

  • Firas Wehbe, MD, PhD (Northwestern University Lurie Cancer Center)

  • James L. Chen, MD; Daniel G. Stover, MD; Maryam B. Lustberg, MD, MPH (The Ohio State University)

  • Janice M. Mehnert, MD (Rutgers Cancer Institute of New Jersey)

  • Sumit A. Shah, MD, MPH; Alokkumar Jha, PhD (Stanford University)

  • Jonathan Riess, MD, MS (University of California, Davis)

  • Rana R. McKay, MD; Angelo Cabal (University of California, San Diego)

  • Aakash Desai, MD, MPH (University of Connecticut)

  • Saurabh Dahiya, MBBS (University of Maryland)

  • Gilberto de Lima Lopes Jr., MD, MBA, FAMS, FASCO (University of Miami/Sylvester Comprehensive Cancer Center)

  • William A. Wood, MD, MPH (UNC Lineberger Comprehensive Cancer Center)

  • Andrew J. Cowan, MD; Ali R. Khaki, MD; Gary H. Lyman, MD, MPH, FASCO, FRCP; Nicole M. Kuderer, MD; Petros Grivas, MD, PhD (University of Washington/Seattle Cancer Care Alliance/Fred Hutch)

  • Brian I. Rini, MD, FACP, FASCO; Samuel M. Rubinstein, MD; Jeremy L. Warner, MD, MS, FAMIA, FASCO (Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center)

  • Keith Stockeri-Goldstein, MD (Washington University in St. Louis/Siteman Cancer Center)

  • Axel Grothey, MD (West Cancer Center)


This is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

Copyright (c) 2020 The Cancer Letter Inc.